drugset
drugset / Trial / NCT01927835

Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa

NCT01927835 ↗

Phase 1 Withdrawn National Institute of Allergy and Infectious Diseases (NIAID) EuroVacc Foundation · collabGlobal Solutions for Infectious Diseases (GSID) · collabHIV Vaccine Trials Network · collabIPPOX Foundation · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immune response to two different HIV vaccine regimens in healthy, HIV-uninfected people in the United States and South Africa.

Timeline

Start
—
Primary completion
2017-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AIDSVAX B/E Vaccine 300 ug Intramuscular
Subject DNA-HIV-PT123 Vaccine 4 mg Intramuscular
Subject NYVAC-HIV-PT1 Vaccine 5e+06 unknown Intramuscular
Subject NYVAC-HIV-PT1 Vaccine 1.2e+08 unknown Intramuscular
Subject NYVAC-HIV-PT4 Vaccine 5e+06 unknown Intramuscular
Subject NYVAC-HIV-PT4 Vaccine 1.1e+07 unknown Intramuscular

Indications

HIV infectious disease